After reproductive senescence or gonadectomy, changes occur in neural gene expression, ultimately altering brain function. The endocrine mechanisms underlying these changes in gene expression beyond immediate hormone loss are poorly understood. To investigate this, we measured changes in gene expression the dorsal striatum, where 17␤-estradiol modulates catecholamine signaling. In human caudate, quantitative PCR determined a significant elevation in ␤1-adrenergic receptor (␤1AR) expression in menopausal females when compared with similarly aged males. No differences were detected in ␤2-adrenergic and D1-and D2-dopamine receptor expression. Consistent with humans, adult ovariectomized female rats exhibited a similar increase in ␤1AR expression when compared with gonadectomized males. No sex difference in ␤1AR expression was detected between intact adults, prepubertal juveniles, or adults gonadectomized before puberty, indicating the necessity of pubertal development and adult ovariectomy. Additionally, increased ␤1AR expression in adult ovariectomized females was not observed if animals were masculinized/ defeminized with testosterone injections as neonates. To generate a model system for assessing functional impact, increased ␤1AR expression was induced in female-derived cultured striatal neurons via exposure to and then removal of hormone-containing serum. Increased ␤1AR action on cAMP formation, cAMP response element-binding protein phosphorylation and gene expression was observed. This up-regulation of ␤1AR action was eliminated with 17␤-estradiol addition to the media, directly implicating this hormone as a regulator of ␤1AR expression. Beyond having implications for the known sex differences in striatal function and pathologies, these data collectively demonstrate that critical periods early in life and at puberty program adult gene responsiveness to hormone loss after gonadectomy and potentially reproductive senescence. (Endocrinology 154: 1820 -1831, 2013) R eproductive senescence or gonadectomy fundamentally changes adult brain function (1, 2), creating differences between pre-and postmenopause and also between age-matched females and males. Indeed, complex changes in gene expression (3, 4) and catecholamine action (5-7) have been widely documented. The endocrine mechanisms causal to these changes beyond the immediate loss of estrogens and other hormones are not well understood, especially given the multiple hormone-sensitive periods throughout life that underlie sexual differentiation (2, 8 -11). Here we investigate how early-life hormonesensitive periods program adult responsiveness to hormone loss, employing catecholamine receptor expression in dorsal striatum as a model system.
R
eproductive senescence or gonadectomy fundamentally changes adult brain function (1, 2) , creating differences between pre-and postmenopause and also between age-matched females and males. Indeed, complex changes in gene expression (3, 4) and catecholamine action (5-7) have been widely documented. The endocrine mechanisms causal to these changes beyond the immediate loss of estrogens and other hormones are not well understood, especially given the multiple hormone-sensitive periods throughout life that underlie sexual differentiation (2, 8 -11) . Here we investigate how early-life hormonesensitive periods program adult responsiveness to hormone loss, employing catecholamine receptor expression in dorsal striatum as a model system.
The dorsal striatum, comprised of the caudate and putamen, receives projections from many brain regions and mediates multiple functions. These include but are not limited to sensorimotor control and aspects of cognition. This brain region is also particularly impacted by pathologies such as Parkinson's disease and drugs of abuse. All of these normal functions and pathologies are modulated by estrogens and show phenotypic sex differences (11) (12) (13) (14) (15) (16) (17) (18) (19) . Organizational and activational hormone and sexlinked genomic effects have been heavily implicated as underlying mechanisms, modulating dopamine and norepinephrine release as well as dopaminergic and adrenergic receptor binding characteristics and/or expression (20 -25) .
The catecholamine receptors, including ␤1-and ␤2-adrenergic and D1-and D2-dopamine receptors, are all highly expressed in human and rodent caudate (26 -30) . Indeed, proper functioning of catecholamine systems is necessary for striatal function, and catecholamine systems are highly sensitive to steroid sex hormone action. Previous studies have shown increases in ␤1-adrenergic receptor density after estrogen loss in the cardiovascular system (31) (32) (33) (34) (35) (36) and in the brain, including the dorsal striatum (37) (38) (39) (40) (41) (42) (43) . We thus focused upon ␤1-adrenergic receptor expression in the dorsal striatum as a model system for studying how early-life endocrine events program how a relevant gene in the nervous system responds to adult steroid sex hormone loss. To that end, here we use quantitative PCR (qPCR) to measure expression of ␤1-adrenergic and other catecholamine receptors in postmenopausal females and age-matched males, male and female rats (an experimentally tractable model system), and male and female primary striatal cell cultures. Broadly, these results provide an example of how early neonatal and pubertal life endocrine events program how the adult nervous system will respond to the effects of menopause and gonadectomy.
Materials and Methods

Human caudate tissue
All protocols were approved by the Internal Review Board at the University of Minnesota. Postmortem samples from human caudate were obtained from the National Disease Research Interchange (http://ndriresource.org; Philadelphia, Pennsylvania). After dissection, tissue was rapidly frozen using liquid nitrogen and placed in RNAlater (QIAGEN, Valencia, California). Tissue was shipped frozen to the University of Minnesota and stored at Ϫ20°C until mRNA extraction. Seven samples were acquired (n ϭ 3 males and 4 females). A priori subject exclusion criteria included known compromising conditions at the time of death: Parkinson's disease, Alzheimer's disease, psychostimulant use, intracranial hemorrhage, anoxia, or thyroidectomy. None of the females were known to receive hormone replacement therapy. The age of menopause onset is not known. There were no significant differences between males and females in all attributes monitored (P Ͼ .05), including time after death to tissue recovery (males, 6.9 Ϯ 0.7 hours; females, 7.6 Ϯ 0.4 hours), tissue recovery time (males, 436.7 Ϯ 177.6 seconds; females, 933.8 Ϯ 157.3 seconds), age (males, 67.7 Ϯ 5.5 years; females, 70.0 Ϯ 3.4 years), and RNA integrity number (males, 5.1 Ϯ 0.6; females, 4.0 Ϯ 0.7). RNA integrity numbers were calculated using the Agilent 2100 Bioanalyzer system and fall within the normal range of human postmortem tissue (44) .
Animals
All protocols were approved by the Animal Care and Use Committee at the University of Minnesota, the University of Michigan, or Harlan Laboratories (Madison, Wisconsin). For experiments carried out in the Mermelstein laboratory, adult male and female intact or gonadectomized Sprague-Dawley rats were purchased from Harlan Laboratories. Animals were bilaterally gonadectomized on postnatal day 60 (P60) at Harlan Laboratories, transported to the University of Minnesota, and then housed in a room maintained at 20°C to 21°C, with a 12-hour light, 12-hour dark cycle and water available ad libitum. Absence of gonads was verified postmortem. Rats were anesthetized with isoflurane and killed on P70. This date was chosen based upon earlier work (38) . The brain was rapidly removed and blocked 3 and 5 mm caudal from the base of the olfactory bulb. The dorsal striatum was microdissected from the anterior brain slice, and the hippocampus was removed from the caudal portion of the brain. All dissections were made in ice-cold modified Hank's balanced salt solution (HBSS) containing (in mM) 4.2 NaHCO 3 and 1 HEPES (pH 7.35, 300 mOsm), as previously described (45, 46) . Tissue was immediately placed into RNAlater. Tissue was stored at 4°C overnight and then at Ϫ20°C until mRNA extraction. Neonatal rats were born in the Mermelstein laboratory colony and group housed with their dam. These animals were killed at P8, and the brain was rapidly removed. Brains from P8 animals were processed the same as adult brains, except they were blocked 2 and 4 mm anterior from the intersection of the midsagittal and transverse sinuses.
For experiments involving neonatal/peripubertal hormone exposure or ovariectomy, male and female Sprague-Dawley rats were born in the Becker laboratory colony and housed 3 to 4 per cage. The animals were housed in a room maintained at 20°C to 21°C, with a 14-hour light, 10-hour dark cycle and free access to phytoestrogen-free rodent chow (2014 Teklad Global, 14% protein rodent maintenance diet, Harlan rat chow; Harlan Teklad, Madison, Wisconsin) and water available ad libitum. On P0 and P1, following a well-established protocol known to masculinize/ defeminize rat brain (47) , female pups received a sc injection of 100 g testosterone propionate in 0.1 mL peanut oil or peanut oil alone. Male pups received peanut oil. Injection sites were sealed with 3M tissue adhesive. On P21, animals were gonadectomized or received a sham surgery using techniques described previously (48) . On P22 to P37, some animals received a daily injection of 0.1 mL peanut oil or 50 g/kg 17␤-estradiol benzoate. On P60, animals were bilaterally gonadectomized or received a sham surgery. All animals were killed on P70. Caudate was microdissected and placed in RNAlater at 4°C overnight and then stored at Ϫ20°C until transport to the University of Minnesota. Upon arrival, tissue was stored at Ϫ20°C until mRNA extraction.
Cell culture
Striatal or hippocampal neurons were cultured from P2 to P3 Sprague-Dawley rat pups as previously described (46, 49) . Male and female cultures were prepared in parallel from pups obtained from the same litter as previously described (50) . Chemicals were purchased from Sigma (St Louis, Missouri) unless stated otherwise. After decapitation, the striatum or hippocampus was isolated in ice-cold modified HBSS containing (in mM) 4.2 NaHCO 3 and 1 HEPES (pH 7.35, 300 mOsm). The tissue was then washed and digested for 5 minutes in a trypsin solution (type XI; 10 mg/mL) containing (in mM) 137 NaCl, 5 KCl, 7 Na 2 HPO 4 , 25 HEPES, and 1500 U deoxyribonuclease (pH 7.2, 300 mOsm). After additional washes with HBSS and HBSS containing 20% fetal bovine serum (FBS) (lots B1090 and L11059; Atlanta Biologicals, Lawrenceville, Georgia), tissue was dissociated and pelleted twice by centrifugation (180g for 10 minutes) to remove contaminants. Cells were then plated onto 10-mm coverslips (treated with Matrigel to promote adherence; BD Biosciences, San Jose, California) and incubated for 20 minutes at 24°C. In normal cultured neuron experiments, neurons were grown in 2 mL per coverslip of MEM (Invitrogen, Grand Island, New York) containing (in mM) 28 glucose, 2.4 NaHCO 3 , 0.0013 transferrin (Calbiochem, La Jolla, California), 2 glutamine, and 0.0042 insulin with 1% B-27 supplement (Invitrogen) and 10% FBS (pH 7.35, 300 mOsm). Culture media did not contain phenol red, and FBS was not charcoal stripped. To inhibit glial growth, 1 mL medium was replaced with a solution containing 4M cytosine 1-␤-D-arabinofuranoside and 5% FBS 48 hours after plating. At 96 hours later, 1 mL medium was replaced with a modified MEM solution containing 5% FBS. Gentamicin (2 g/mL; Invitrogen) was added to all media solutions to eliminate bacterial growth. In serum-free cultured neuron experiments, FBS was not added to media.
Quantitative PCR
The qPCR was performed using standard protocols (46, 51) . mRNA was extracted and reverse transcribed from cultured neurons or brain tissue using standard kits (RNAeasy Mini or Midi Kit and QuantiTect Reverse Transcription Kit from QIAGEN and Transcriptor First-Strand cDNA Synthesis Kit from Roche Diagnostics, Indianapolis, Indiana). Some qPCR amplification was performed using RT2 Real-Time SYBR Green PCR master mix PA-010 (SABiosciences, Frederick, Maryland) or QuantiFast SYBR Green PCR master mix (QIAGEN) on an Opticon 2 PCR machine (MJ Research, Schaumburg, Illinois). No differences in experimental results were found between SYBRs. The critical cycle threshold was set at 25 SDs above baseline and standardized to the ribosome-related gene rpl13a. The thermal cycling program used for the RT2 Real-Time SYBR was an initial denaturing step at 95°C for 11 minutes, followed by at least 30 cycles consisting of a 15-second denaturing step at 95°C, annealing step for 35 seconds at 55°C, an extension step for 30 seconds at 72°C, and a measurement of fluorescent intensity. The thermal cycling program used with QuantiFast SYBR was an initial denaturing step at 95°C for 6 minutes, followed by at least 30 cycles consisting of a 10-second denaturing step at 95°C, annealing/extension step for 30 seconds at 60°C, and a measurement of fluorescent intensity. Other qPCR amplifications were performed using LightCycler 480 SYBR Green I Master Mix (Roche) on a LightCycler 480 II PCR machine (Roche). Threshold values were calculated using the second derivative max method and standardized to the ribosome-related gene rpl13a (LightCycler 480 software version 1.5; Roche). The thermal cycling program used was a preincubation step at 95°C for 5 minutes, followed by at least 45 cycles consisting of a 10-second denaturing step at 95°C, annealing step for 10 seconds at 60°C, an extension step for 10 seconds at 72°C, and a measurement of fluorescent intensity. At the end of each cycling program, a melting curve was run. PCR products were sequenced for verification of product identity. PCR for individual cDNA samples was performed in triplicate, and overall experiments were repeated at least twice. No differences in experimental results were found between PCR machines or SYBR.
The upper and lower primer sequences used for humans were as follows: rpl13a (GenBank accession number NM_012423.2), 5Ј-GCCCTCAAGGTCGTGCGTCTG-3Ј and 5Ј-CCAGCTTC-CTATGTCCCAGGGCTGC-3Ј; adrb1 (GenBank accession number NM_000684.2), 5Ј-ACCCCAAGTGCTGCGATTTC-GT-3Ј and 5Ј-GCTCGCAGCTGTCGATCTTCTT-3Ј; adrb2 (GenBank accession number NM_000024.5), 5Ј-GTGATCG-CAGTGGATCGCTA-3Ј and 5Ј-AGTTGATGGCTTCCTG-GTGG-3Ј; drd1a (GenBank accession number NM_000794.3), 5Ј-TGGGTGGGCGAATTCTTCCCTGAA-3Ј and 5Ј-GCCC-CATTGTTGTTAATGCTCACCG-3Ј; and drd2 (GenBank accession number NM_016574.3 and NM_000795.3, a shared sequence across both human drd2 isoforms), 5Ј-ATGTGTGT-GATGAAGAAGGGCAGCC-3Ј and 5Ј-ATGCCCAATGG-CAAAACCCGGA-3Ј.
The upper and lower primer sequences used for rats were as follows: rpl13a (GenBank accession number NM_173340), 5Ј-TGCTGCCGCACAAGACCAAA-3Ј and 5Ј-AACTTTCTGG-TAGGCTTCAGCCGC-3Ј (46); adrb1 (GenBank accession number NM_012701), 5Ј-ACCCCAAGTGCTGCGATTTC-GT-3Ј and 5Ј-GCTCGCAGCTGTCGATCTTCTT-3Ј (46); adrb2 (GenBank accession number NM_012492.2), 5Ј-TTCT-GTGCCTTCGCCGGTCTTCTT-3Ј and 5Ј-ATGCCAGGG-GCTTCCTCACAAA-3Ј; drd1a (GenBank accession number NM_012546.2), 5Ј-TGGGTGGGCGAATTCTTCCCTGAA-3Ј and 5Ј-GCCCCATTGTTGTTAATGCTCACCG-3Ј; drd2 (GenBank accession number NM_012547.1), 5Ј-ATGC-CCAATGGCAAAACCCGGA-3Ј and 5Ј-ATGTGCGTGAT-GAAGAAGGGCAGCCA-3Ј; and ngf (GenBank accession number XM_227525.4), 5Ј-GCAGTGCCCCTGCTGAACCA-3Ј and 5Ј-TCCGAAGAGGTGGGTGGAGGC-3Ј.
For select qPCR experiments, before mRNA extraction, cultured striatal neurons were incubated in Tyrode's solution containing tetrodotoxin (1M) and AP-5 (25M) at 24°C for 3 hours and then stimulated with isoproterenol (10M) or vehicle for 2 hours.
cAMP assay
Using previously described protocols (46, 52), we measured cAMP concentrations in cultured striatal neurons (8 -9 days in vitro) using a Parameter cAMP kit (R&D Systems, Minneapolis, Minnesota). Cells were incubated in a Tyrode's solution containing tetrodotoxin (1M; Sigma) and AP-5 (25M; Sigma) at 24°C for 3.0 hours. Cell stimulations were performed as follows: vehicle for 10 minutes and isoproterenol for 10 minutes (10M; Sigma). Each experiment was performed at least 3 times to verify results.
Immunocytochemistry
Immunocytochemistry protocols followed those described previously (46, 53) . Briefly, cultured striatal or hippocampal neurons at 8 to 9 days in vitro were incubated in a Tyrode's solution containing tetrodotoxin (1M) and AP-5 (25M) at 24°C for 3.0 hours. Some neurons were exposed to 17␤-estradiol (1nM; Tocris, Ellisville, Missouri) in MEM or MEM alone (Invitrogen) for 24 hours before incubation in 17␤-estradiol in Tyrode's solution or Tyrode's solution alone. Cell stimulations were performed as follows: vehicle for 10 minutes, isoproterenol for 10 minutes (10M; Sigma), 6-chloro-PB for 10 minutes (500nM; Sigma), and 20mM K ϩ for 5 minutes. After fixation, permeabilization, and blocking, cells were incubated at 37°C for 1 hour in blocking solution containing a monoclonal antibody directed against serine 133 phosphorylated cAMP response element-binding protein (CREB) (1:1000, 05-667; Upstate Biotechnology, Lake Placid, New York), and to identify individual cell morphology, a polyclonal antibody targeting microtubuleassociated protein 2 (1:1000, AB5622; Calbiochem). Cells were exposed to Alexa Fluor 488-conjugated antirabbit and 635-conjugated antimouse (Invitrogen, Carlsbad, California) secondary antibodies for visualization of microtubule-associated protein 2 and phosphorylated CREB, respectively. After mounting, nuclear fluorescent intensities for phosphorylated CREB were blindly acquired using a Leica DM5500Q confocal system and quantified using Leica LAS AF (version 1.9.0; Leica, Deerfield, Illinois). Intensities of randomly selected neurons (n Ն 30 per group) were measured blind following established protocols described in detail elsewhere (46) . Each experiment was performed at least 3 times to verify results.
Statistics
Experiments were analyzed using 2-tailed Student's t tests, or 1-or 2-way ANOVA and Tukey's multiple-comparison post hoc tests (Prism version 4.03 from GraphPad Software, La Jolla, California, and SigmaStat version 3.00 from Systat, Chicago, Illinois). Statistical differences between treatment groups are depicted within each figure as different alphabetical characters. Probability values Ͻ .05 were considered a priori as significant. Data are presented as mean Ϯ SEM.
Results
Postmenopausal, aged women show increased ␤1-adrenergic receptor expression in the caudate compared with agematched males Given the important role of catecholamines in caudate function, and the known sex differences in these systems, we used qPCR to assess ␤1-and ␤2-adrenergic and D1-and and D2-dopamine receptor expression in human caudate from postmenopausal females and agematched males. ␤1-Adrenergic receptor expression was elevated in female caudate compared with agematched males ( Figure 1A , P ϭ .0076). No other sex differences were detected ( Figure 1 , B-D, P Ͼ .05). This sex difference could be generated via a direct genomic effect, generated by a direct result of loss of hormones after menopause or by other aging processes that differ between males and females. Acquiring tissue from young humans (both premenopausal and those with their ovaries removed) or adult females undergoing hormone replacement therapy without confounding conditions was not feasible for this study. Thus, we continue with studies in ovariectomized rats. Ovariectomized rats have been previously demonstrated to model various aspects of hormone loss associated with menopause (1), with known limitations including abrupt onset, and lack of perimenopause and associated hormonal cycling.
Increased ␤1-adrenergic receptor expression in adult females relies on neonatal feminization and puberty followed by the loss of ovarian function during adulthood In the first set of experiments, male and female rats were gonadectomized on P60 (Figure 2A) , whereas a second group was left intact ( Figure 2B ). The dorsal striatum (caudate/putamen) from all groups was collected on P70. Gene expression in the gonadectomized rats recapitulated that observed in human caudate, with ␤1-adrenergic receptor expression increased in females compared with males (Figure 2A ; P ϭ .036), with no other sex differences (P Ͼ .05). In contrast, intact animals exhibited no sex differences in any of the genes assayed (Figures 2B; P Ͼ .05). Hence, this sex difference in ␤1-adrenergic receptor expression is dependent on the loss of ovarian function.
To determine whether this sex difference is due to a simple lack of circulating ovarian hormones or whether developmental processes also play a role, we assessed receptor expression in P8 animals. At this early, prepubertal age, ovarian activity is quiescent. No sex differences in ␤1-adrenergic receptor expression were detected at P8 ( Figure 3A ; P Ͼ .05), indicating increased ␤1-adrenergic receptor is not simply due to a lack of ovarian hormones but that developmental processes must first occur. No sex differences were detected in D1-or D2-dopamine or ␤2-adrenergic receptor expression at P8 (P Ͼ .05 for all). We thus next established whether a peripubertal critical period is necessary for the observed increase in ␤1-adrenergic receptor expression and whether peripubertal 17␤-estradiol exposure alone is sufficient for increased adult ␤1-adrenergic receptor expression. There were 3 treatment groups. Animals were either ovariectomized or received a sham surgery before puberty on P21. Between P22 and P37 (during the peripubertal period), animals were injected daily for 3 days with either vehicle or 50 g/kg 17␤-estradiol benzoate in peanut oil and then 1 day of no injection. This cycle was repeated 4 times, ending on P37. On P60 (adulthood/postpuberty), animals received either ovariectomy or sham surgery. Caudate from all 3 groups was collected on P70. Females ovariectomized after puberty (P60) exhibited increased ␤1-adrenergic receptor expression compared with those ovariectomized before puberty (P21) and not receiving peripubertal 17␤-estradiol ( Figure 3B ; overall ANOVA, P ϭ .0438; post hoc, P Ͻ .05). This indicates that the presence of ovaries during a peripubertal period (and potentially during adulthood) was necessary for the increase in receptor expression after loss of ovarian function in the adult. ␤1-Adrenergic receptor expression in females ovariectomized before puberty (P21) exposed to peripubertal 17␤-estradiol did not significantly differ from either of the other 2 groups (P Ͼ .05 for both), with absolute expression level being more comparable to that of females ovariectomized on P21. These data argue that peripubertal 17␤-estradiol exposure alone may not be sufficient for inducing increased ␤1-adrenergic receptor expression. As a control, no difference was detected in D2-dopamine receptor expression among the 3 groups (P Ͼ .05).
Around the time of birth, the testes of male rats produce testosterone. This process masculinizes and defeminizes neural tissue and would have occurred in all experiments described thus far. Female testosterone levels at this age are low or nondetectable, although we note that they are exposed to some steroid sex hormones in utero. To test whether the lack of neonatal testosterone is essential for adult sex differences in ␤1-adrenergic receptor expression, we injected female neonate rat pups with either vehicle or testosterone on P0 and P1; males were injected with vehicle. All animals received a sham surgery on P21 and were gonadectomized as adults on P60. ␤1-Adrenergic receptor expression was measured on P70 ( Figure 3C ). As expected, there was a sex difference between vehicle-treated animals. In contrast, testosterone injections masculinized/ defeminized ␤1-adrenergic receptor expression in female animals ( Figure 3C ; P ϭ .0064). No significant differences were found between groups in D2-dopamine receptor expression (P Ͼ .05). This finding supports the hypothesis that early masculinizing/defeminizing testosterone exposure eliminates estrogenic regulation of ␤1-adrenergic receptor expression in the adult. This could occur by acting to directly masculinize/defeminize neural tissue or by possibly shutting down pubertal/adult ovary function (54, 55) .
Increased ␤1-adrenergic receptor expression leads to functional sex differences in cellular physiology
Primary neuronal cultures were used to establish a model system in which to assess the functional significance of increased ␤1-adrenergic receptor expression. Striatal cultures were generated from pups aged 2 to 3 days, after the initial hormone surge occurs in males but not females ( Figure 4A ). These sex-specific cultures were placed in either serum-free (hormone-free) media or media containing serum. Nine days later, all cultures were placed in serum-free media for at least 3 hours to induce hormone loss before cell lysis and qPCR. Striatal neurons raised in serum-free media did not show a difference in ␤1-adrenergic receptor expression after exposure to additional serum-free media ( Figure 4B ; P Ͼ .05). In contrast, striatal neurons raised in hormone-containing media and then exposed to serum-free media showed increased ␤1-adrenergic receptor expression in female-derived cultures ( Figure  4B ; P ϭ .0376). As an additional control, there were no observed sex differences in D1-or D2-dopamine receptor expression (Table 1 ; P Ͼ .05).
Sex differences in ␤1-adrenergic receptor expression in the striatal cultures afforded the ability to assess functional cellular relevance. Hence, we assessed the effects of ␤1-adrenergic receptor stimulation on downstream cAMP formation, CREB phosphorylation, and target gene expression (ie, nerve growth factor [NGF]). For experiments measuring cAMP and CREB phosphorylation, serumcontaining cultures were treated as described above followed by 10 minutes stimulation with isoproterenol (ISO) ( Figure 4C ). Under these experimental conditions, ISO predominantly stimulates the ␤1-adrenergic receptor (46) . ISO-exposed female striatal neurons exhibited increased cAMP formation compared with ISO-exposed male cultures ( Figure 4D ; effect of sex, P ϭ .020; effect of drug, Figure 3 . Natal and peripubertal hormone-sensitive periods program adult ␤1-adrenergic receptor gene expression sensitivity to ovariectomy. A, qPCR analysis of ␤1-and ␤2-adrenergic and D1-and D2-dopamine receptor expression in prepubertal rat (P8). No sex differences were detected. B, Prepubertal ovariectomy eliminates increased ␤1-adrenergic receptor expression in females, and cyclic peripubertal 17␤-estradiol exposure is not sufficient to induce increased ␤1-adrenergic receptor expression. Experimental protocol is shown on the left. Females were ovariectomized or experienced sham surgery on P21 and P60. Between P22 and P37, animals were injected daily for 3 days with 17␤-estradiol or vehicle, and then there was 1 day of no injection. This cycle was repeated 4 times, ending on P37. On the right is shown ␤1-adrenergic receptor expression in female rat caudate/putamen. Data are normalized to OVX 21 expression. C, Masculinization/defeminization induced by early hormone exposure blocks sex differences in ␤1-adrenergic receptor expression. Left: Experimental protocol. Right: Neonatal testosterone exposure blocks the ovariectomy-induced increase in ␤1-adrenergic receptor expression. Bar color and letters indicate statistically significantly different groups. Abbreviations: ␤1AR, ␤1-adrenergic receptor; ␤2AR, ␤2-adrenergic receptor; D1DAR, D1-dopamine receptor; D2DAR, D2-dopamine receptor; OVX, ovariectomized; TES, testosterone; Veh, vehicle. Figure 4E ; effect of sex, P ϭ .036; effect of drug, P Ͻ .001; interaction of sex and drug, P ϭ .040; post hoc, female ISO compared with male ISO, P ϭ .004).
As a control, we stimulated D1-dopamine receptors with 6-chloro PB. CREB phosphorylation induced by the D1-dopamine receptor agonist 6-chloro PB did not differ by sex (Table 1 ; effect of sex, P Ͼ .05; effect of drug, P Ͻ .001; interaction of sex and drug, P Ͼ .05). Because the D1-dopamine and the ␤1-adrenergic receptor are coexpressed in medium spiny neurons (56) and activate similar signal transduction pathways, this controlled for a potential sex differences in downstream signal transduction molecules. We also tested the regional specificity of the sex difference in ␤1-adrenergic receptor expression by examining ␤1-adrenergic receptor expression in cultured hippocampal neurons. We found no sex differences in ␤1-adrenergic receptor expression in cultured hippocampal neurons (Table 1 ; P Ͼ .05). Similarly, ISO-induced CREB phosphorylation in hippocampal cultures did not differ by sex (Table 1 ; effect of sex, P Ͼ .05; effect of drug, P Ͻ .001; interaction of sex and drug, P Ͼ .05). These in vitro data are consistent with in vivo catecholamine receptor expression, because no sex differences in ␤1-or ␤2-adrenergic or D1-or D2-dopamine receptor expression were detected in adult hippocampus from gonadectomized or intact rats (Table 2 ; P Ͼ .05 for all comparisons). These sex differences in cAMP formation and CREB phosphorylation could also lead to sex differences in a target gene regulated by this pathway. For this experiment, we examined changes in NGF expression, which is regulated by CREB and produced by the striatum (57) to locally affect striatal neurons (58) . A 2-hour exposure to ISO produced increased expression of NGF in female striatal neurons compared with male ( Figure 4F ; effect of sex, P ϭ .043; effect of drug, P Ͻ .001; interaction of sex and drug, P Ͻ .001; post hoc, female ISO compared with male ISO, P Ͻ .001). Of note, we additionally found that baseline NGF levels differed between males and females (P ϭ .029), with female expression lower than male. Collectively, these data indicate that sex differences in ␤1-adrenergic receptor expression have functional impacts upon cellular physiology.
17␤-Estradiol down-regulates ␤1-adrenergic receptor action
Across multiple organs and in other brain regions, ␤1-adrenergic receptor expression in the adult animal is sensitive to 17␤-estradiol. 17␤-Estradiol, along with many Figure 4 . Increases in ␤1-adrenergic receptor expression impacts cellular physiology and is blocked by 17␤-estradiol. A, Experimental protocol: increased ␤1-adrenergic receptor expression can be induced in vitro using primary cultured female striatal neurons. B, Neurons continuously grown in serum-free media do not exhibit sex differences in ␤1-adrenergic receptor (␤1AR) expression (left); ␤1-adrenergic receptor expression shows sex differences in striatal-neuron cultures first exposed to hormone-containing serum and then placed in serumfree Tyrode's solution for at least 3 hours (right). C, Sex differences in ␤1-adrenergic receptor expression differentially impact male and female cellular physiology. D, The ␤-adrenergic receptor agonist ISO induces sex differences in cAMP formation. The effects of ISO in this paradigm have been previously shown to be ␤1-adrenergic receptorspecific (see Results). E, ISO-induced CREB phosphorylation shows sex differences. F, ISO exposure induces sex differences in NGF gene expression. G, Experimental protocol to test whether 17␤-estradiol exposure is sufficient to block sex differences in ␤1-adrenergic receptor action after feminization. H, 17␤-Estradiol exposure blocks increased ␤1-adrenergic receptor action in female cultures. Striatal neurons exposed to vehicle show sex differences in ISO-induced phosphorylation of CREB, whereas neurons exposed to 17␤-estradiol do not. Bar color and letters indicate statistically significantly different groups.
other hormones and relevant molecules, is present in the serum used to induce increased ␤1-adrenergic receptor expression in the cultured striatal neurons. To test whether 17␤-estradiol treatment alone is sufficient to block the up-regulation in ␤1-adrenergic receptor action after serum deprivation, male-and female-derived cultures were treated as described above, except that the serum-free media contained either vehicle or 1nM 17␤-estradiol. Similar to Figure 4E , vehicle in the serum-free media did not block the sex difference in ISO-induced CREB phosphorylation between male and female cultures ( Figure 4H ). In contrast, adding 17␤-estradiol to the serum-free media eliminated this sex difference (vehicle group: effect of sex, P ϭ .010; effect of drug, P Ͻ .001; interaction of sex and drug, P ϭ .004; post hoc, female ISO compared with male ISO, P Ͻ .001; 17␤-estradiol group: effect of sex, P Ͼ .05; effect of ISO, P Ͻ .001; interaction of sex and drug, P Ͼ .05; post hoc, female ISO compared with male ISO, P Ͼ .05) This result is consistent with the model that 17␤-estradiol is sufficient to prevent up-regulation of the ␤1-adrenergic receptor.
Discussion
Here we present data generated from humans to cultured neurons that collectively argue that critical hormone-sensitive organizational periods early in life directly sensitize adult gene responsiveness to loss of gonadal hormones after ovariectomy, and possibly menopause ( Figure 5 ). In experiments with human postmortem caudate tissue, we found that ␤1-adrenergic receptor expression was in- creased in menopausal human females compared with age-matched males. Then, using ovariectomized rats as a standard model for loss of hormone effects after menopause, we found that ␤1-adrenergic receptor expression was increased in gonadectomized but not intact female rats compared with males. To elucidate the underlying endocrine mechanisms, we determined that this sex difference was eliminated by prepubertal ovariectomy or early masculinizing/defeminizing hormone exposure, consistent with data from other model systems indicating a peripubertal steroid sex hormone-sensitive period beyond the pre/neonatal critical period (8, 9) . Sex differences in ␤1-adrenergic receptor expression were then induced in cultured striatal neurons, determining that differences in ␤1-adrenergic receptor expression directly impact cellular physiology. Broadly, these findings provide a specific example of how early life hormone-sensitive periods program how neural gene expression responds to hormone loss associated with menopausal/ovariectomy. Increased striatal ␤1-adrenergic receptor expression induced by loss of ovary function joins a large literature indicating estrogenic influence on ␤-adrenergic receptor expression and function in and outside the nervous system. The first hint of this relationship dates to at least the 1960s, when it was discovered that the effects of norepinephrine on vascular reactivity was more potent in pregnant than in nonpregnant human females (59) . In 1976, it was reported that estrogens reduced ␤-adrenergic receptor modulation of rat vascular reactivity (31) . These initial reports in the vascular system foreshadowed later research in many systems, including but not limited to cardiac muscle (35) , myometrium (60) , and brown adipose cells (61) , all of which report 17␤-estradiol down-regulating ␤-adrenergic receptor action or density. Likewise, ovariectomy up-regulated ␤1-adrenergic receptors in rat heart (32) . In rat brain, 17␤-estradiol has direct actions on norepinephrine-producing neurons and receptors (39) , and rat locus coeruleus cell number and volume increase in females during puberty (62) . Measured using autoradiographic receptor binding, 17␤-estradiol exposure decreases ␤-adrenergic receptor responses and/or density in rat cortex, olfactory bulb, striatum (42) , and hypothalamus (39) . As predicted, ovariectomy increased ␤-adrenergic receptor density in cortex and hypothalamus (38) . Exposure to 17␤-estradiol can also uncouple the associated signaling transduction pathway, at least in the hypothalamus (39) . We conclude from these studies that loss of 17␤-estradiol generally up-regulates ␤-adrenergic receptor expression and action.
This conclusion was supported by our studies using primary cultured striatal neurons, where 17␤-estradiol exposure eliminated sex differences in ␤1-adrenergic receptor action. Increased ␤1-adrenergic receptor expression was induced by first harvesting striatal neurons from female animals after the first pre/neonatal masculinization/ defeminization period, by providing hormone-containing serum during the neuron growth phase and then by removing serum. Providing 17␤-estradiol during serum removal prevented increased ␤1-adrenergic receptor action. This protocol does not necessarily mimic in vivo processes per se but instead establishes that 17␤-estradiol and potentially other hormones act relatively rapidly and directly on striatal neurons to program gene expression. This is consistent with the rapid signaling of membrane-associated ␣-and ␤-estrogen receptors expressed by both medium spiny neurons and cholinergic interneurons (20, (63) (64) (65) (66) and the sex differences exhibited in some cellular properties (67) (68) (69) (70) .
The use of primary cultured striatal neurons enabled clear tests of whether sex differences in ␤1-adrenergic receptor expression led to functional consequences for cellular physiology. We assessed this by turning to the downstream action of the ␤1-adrenergic receptor on cellular physiology, given that we were unable to generate quality Western blots of the ␤1-adrenergic receptor to directly assess protein levels. To address this limitation, we reasoned that if a sex difference in functional, membraneassociated ␤1-adrenergic receptor protein exists, then receptor stimulation should likewise induce sex differences in downstream target molecules. Thus, we employed the cultured striatal neuron model and measured cAMP formation, CREB phosphorylation, and target gene expression (ie, NGF). Given the sex differences in these measurable endpoints after ␤1-adrenergic receptor stimulation, we conclude that functional sex differences exist in membrane ␤1-adrenergic receptor expression, consistent with classical studies measuring ␤1-adrenergic receptor density (42, 71) .
Adrenergic receptor action in the caudate was understudied for many years, especially beginning in the late 1970s after dopamine (instead of norepinephrine) was established as the primary reward neuromodulator. This model, however, is being augmented by both older and more recent experiments that show abundant ␤1-adrenergic receptor expression in human caudate (29) and rat striatum on both D1-and D2-dopamine receptor-expressing medium spiny neurons (46, 56) and cholinergic interneurons (72) . Likewise, norepinephrine is present in the striatum (although at lower levels than dopamine) (73) , reflecting sparse noradrenergic projections from the locus coeruleus and brainstem nuclei (74) . This projection may be sexually dimorphic, because norepinephrine levels are greater in females than in males and vary across the ovarian cycle (23) and rat locus coeruleus cell number and volume are increased in females compared with males (62) . Like dopamine, extracellular concentrations of norepinephrine are increased by psychostimulant exposure (75) and reduced in Parkinson's disease (76) , with the ␤-adrenergic receptor antagonist propranolol modulating locomotor responses in both contexts (77, 78) . We note that there is also evidence that dopamine can activate ␤-adrenergic and especially ␣-adrenergic receptors (72, 79 -81) .
The clear effect of estrogens on ␤1-adrenergic receptor function is a direct contrast to estrogenic effects on dopamine neurotransmission and receptor expression. Although it is clear that 17␤-estradiol increases dopamine release in the caudate, the effects of 17␤-estradiol on dopamine receptors are more complex (22, 82) . Consistent with the current study, most investigators find little evidence for sex differences or 17␤-estradiol effects upon dopamine receptor mRNA expression (21, 83) . Rather, 17␤-estradiol effects on dopamine receptor density are usually detected using receptor-binding techniques (20, 22, 84 -86) . Indeed, one study that measured D2-dopamine receptors 14 days after ovariectomy in rats found differences using receptor binding but not PCR (86) . This suggests that 17␤-estradiol modulates dopamine receptor action after transcription, consistent with a rapid, nonclassical 17␤-estradiol action on striatal dopamine receptors. The studies cited above were conducted in rodents. We are aware of only one human study, which detected no significant sex difference in D2-dopamine receptor density (87) .
Given the caudate's integral role in sensorimotor function, it is tempting to speculate that increased ␤1-adrenergic receptor expression after adult hormone loss may play a role in the known pathologies associated with this brain region. For instance, one characteristic behavioral phenotype of Parkinson's disease, bradykinesia, is caused by loss of neurons in the substantia nigra that produce dopamine and neurons in the locus coeruleus that produce norepinephrine, thereby compromising striatal function. The most common treatment for this pathology is the dopamine/norepinephrine precursor L-DOPA (L-3,4-dihydroxyphenylalanine), which attenuates bradykinesia but can induce dyskinesia. L-DOPA-induced dyskinesia is more prevalent in females than in males (88) , although women have an overall lower incidence of Parkinson's disease (18) . Because more ␤1-adrenergic receptors are expressed in menopausal females than in males, this may provide more opportunity for norepinephrine and perhaps dopamine to influence neuronal function. Consistent with this speculation, the ␤-adrenergic receptor antagonist propranolol reduces or eliminates L-DOPA-induced dyskinesia in human Parkinson's disease patients and rat models (78, 89) . Propranolol is also recommended as a firstline therapy for tardive dyskinesia (90), a pathology modulated by steroid sex hormones (22) .
